Zhao Cui Selected Research

Hemoptysis

1/2021	Laminin-521 is a Novel Target of Autoantibodies Associated with Lung Hemorrhage in Anti-GBM Disease.
4/2011	Clinical features and outcomes of anti-glomerular basement membrane disease in older patients.
1/2007	Characteristics and outcome of Chinese patients with both antineutrophil cytoplasmic antibody and antiglomerular basement membrane antibodies.
10/2004	[The distribution and clinical significance of IgG subclasses of anti-glomerular basement membrane antibodies].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhao Cui Research Topics

Disease

37	Anti-Glomerular Basement Membrane Disease (Goodpasture's Syndrome) 12/2022 - 10/2004
22	Membranous Glomerulonephritis (Membranous Nephropathy) 12/2022 - 08/2013
18	Proteinuria 07/2022 - 10/2004
14	Glomerulonephritis 01/2020 - 07/2005
9	Autoimmune Diseases (Autoimmune Disease) 10/2020 - 01/2007
8	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 11/2019 - 09/2010
7	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 12/2013
6	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 01/2022 - 08/2013
5	Hemorrhage 01/2021 - 01/2005
5	Renal Insufficiency (Renal Failure) 09/2017 - 06/2009
4	Neoplasms (Cancer) 07/2022 - 10/2017
4	Hemoptysis 01/2021 - 10/2004
4	Nephritis 01/2020 - 06/2009
4	Anuria 11/2019 - 01/2005
4	Vasculitis (Vasculitides) 11/2019 - 01/2010
4	Oliguria 04/2014 - 01/2005
3	Wounds and Injuries (Trauma) 07/2022 - 01/2020
3	Infections 06/2021 - 01/2017
3	Kidney Diseases (Kidney Disease) 01/2020 - 11/2018
2	Lipoid Nephrosis (Glomerulonephritis, Minimal Change) 01/2022 - 08/2013
2	Chronic Renal Insufficiency 01/2020 - 11/2018
2	Hematuria 01/2020 - 10/2004
2	Interstitial Nephritis (Tubulointerstitial Nephritis) 11/2019 - 05/2017
2	Nephrotic Syndrome (Syndrome, Nephrotic) 01/2018 - 11/2017
2	Disease Progression 01/2018 - 01/2016
2	IGA Glomerulonephritis (IGA Nephropathy) 01/2016 - 09/2008
2	Esophageal Achalasia (Megaesophagus) 01/2015 - 04/2014
2	Systemic Vasculitis 12/2013 - 01/2007
2	Necrosis 03/2013 - 01/2010
2	Microscopic Polyangiitis 07/2011 - 11/2010
1	Immune System Diseases (Immune Disorders) 12/2022
1	Liver Neoplasms (Liver Cancer) 01/2022
1	Hematoma 12/2021
1	Shock 12/2021
1	Urolithiasis 12/2021
1	Lung Injury 01/2021
1	Amyloidosis 06/2020
1	Birth Weight (Birth Weights) 01/2020
1	Fibrosis (Cirrhosis) 01/2020
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2020
1	Sclerosis 11/2019
1	Acute Tubulointerstitial Nephritis 11/2019

Drug/Important Bio-Agent (IBA)

29	AntibodiesIBA 12/2022 - 04/2005
22	antiglomerular basement membrane antibodyIBA 01/2021 - 10/2004
17	CreatinineIBA 07/2022 - 01/2005
17	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 11/2019 - 10/2004
15	AutoantibodiesIBA 12/2022 - 07/2005
15	EpitopesIBA 01/2021 - 08/2007
14	Immunoglobulin G (IgG)IBA 07/2022 - 10/2004
9	Peptides (Polypeptides)IBA 01/2020 - 04/2016
8	Phospholipase A2 ReceptorsIBA 12/2022 - 05/2017
8	Peroxidase (Myeloperoxidase)IBA 10/2019 - 11/2010
6	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2011
6	AutoantigensIBA 01/2021 - 06/2012
5	AntigensIBA 12/2022 - 04/2016
5	Complement System Proteins (Complement)IBA 07/2022 - 01/2013
5	Immunoglobulin M (IgM)IBA 01/2020 - 01/2006
4	Rituximab (Mabthera)FDA Link 12/2022 - 01/2018
4	HLA-DRB1 Chains (HLA DRB1)IBA 01/2020 - 11/2009
4	Amino Acids FDA Link 10/2019 - 05/2011
3	CollagenIBA 01/2021 - 08/2007
3	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 01/2020 - 01/2013
3	Adrenal Cortex Hormones (Corticosteroids)IBA 11/2019 - 09/2011
3	ThrombospondinsIBA 01/2019 - 10/2017
3	anti-glomerular basement membrane autoantibodyIBA 01/2018 - 11/2009
2	Complement C3a (Complement 3a)IBA 07/2022 - 01/2020
2	Immunosuppressive Agents (Immunosuppressants)IBA 01/2022 - 09/2008
2	artenimol (dihydroartemisinin)IBA 01/2022 - 01/2019
2	AlbuminsIBA 10/2018 - 05/2016
2	HLA Antigens (Human Leukocyte Antigens)IBA 07/2015 - 05/2011
2	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 05/2014 - 08/2013
2	Complement C3 (C3 Complement)IBA 01/2014 - 01/2013
2	Complement Factor B (Factor B)IBA 01/2014 - 01/2013
2	Mannose-Binding Lectin (Mannan-Binding Lectin)IBA 01/2014 - 01/2013
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 09/2011 - 09/2008
1	andrographolideIBA 07/2022
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 07/2022
1	ProteomeIBA 07/2022
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 07/2022
1	Leflunomide (Arava)FDA LinkGeneric 01/2022
1	Sorafenib (BAY 43-9006)FDA Link 01/2022
1	SteroidsIBA 01/2022
1	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2022
1	Interleukin-10 (Interleukin 10)IBA 01/2022
1	Therapeutic UsesIBA 01/2022
1	artemisinin (artemisinine)IBA 06/2021
1	MercuryIBA 01/2021
1	Chemotactic FactorsIBA 06/2020
1	Serum AlbuminIBA 01/2020
1	B-Lymphocyte Epitopes (B-Cell Epitope)IBA 01/2020
1	Urokinase Plasminogen Activator ReceptorsIBA 01/2020
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020
1	Growth Hormone (Somatotropin)IBA 11/2019
1	TinIBA 11/2019
1	HLA-DQ Antigens (HLA-DQ)IBA 10/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019

Therapy/Procedure

9	Therapeutics 12/2022 - 07/2011
2	Plasma Exchange 05/2019 - 01/2016
2	Myotomy 01/2015 - 04/2014
1	Lithotripsy (Extracorporeal Shockwave Lithotripsy) 12/2021